These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26916334)

  • 41. Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer Disease and Hereditary Spastic Paraplegia.
    Zempel H; Mandelkow EM
    Mol Neurodegener; 2015 Dec; 10():68. PubMed ID: 26691836
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model.
    Kim Y; Choi H; Lee W; Park H; Kam TI; Hong SH; Nah J; Jung S; Shin B; Lee H; Choi TY; Choo H; Kim KK; Choi SY; Kayed R; Jung YK
    Neurobiol Dis; 2016 Mar; 87():19-28. PubMed ID: 26704708
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study.
    Chaney AM; Lopez-Picon FR; Serrière S; Wang R; Bochicchio D; Webb SD; Vandesquille M; Harte MK; Georgiadou C; Lawrence C; Busson J; Vercouillie J; Tauber C; Buron F; Routier S; Reekie T; Snellman A; Kassiou M; Rokka J; Davies KE; Rinne JO; Salih DA; Edwards FA; Orton LD; Williams SR; Chalon S; Boutin H
    Theranostics; 2021; 11(14):6644-6667. PubMed ID: 34093845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity.
    Decker JM; Krüger L; Sydow A; Dennissen FJ; Siskova Z; Mandelkow E; Mandelkow EM
    EMBO Rep; 2016 Apr; 17(4):552-69. PubMed ID: 26931569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease.
    Choi SH; Aid S; Caracciolo L; Minami SS; Niikura T; Matsuoka Y; Turner RS; Mattson MP; Bosetti F
    J Neurochem; 2013 Jan; 124(1):59-68. PubMed ID: 23083210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spreading of Tau Protein Does Not Depend on Aggregation Propensity.
    Rodrigues S; Anglada-Huguet M; Hochgräfe K; Kaniyappan S; Wegmann S; Mandelkow EM
    J Mol Neurosci; 2023 Oct; 73(9-10):693-712. PubMed ID: 37606769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer's disease.
    Sun XY; Li LJ; Dong QX; Zhu J; Huang YR; Hou SJ; Yu XL; Liu RT
    J Neuroinflammation; 2021 Jun; 18(1):131. PubMed ID: 34116706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Developmental Pathogenicity of 4-Repeat Human Tau Is Lost with the P301L Mutation in Genetically Matched Tau-Transgenic Mice.
    Gamache JE; Kemper L; Steuer E; Leinonen-Wright K; Choquette JM; Hlynialuk C; Benzow K; Vossel KA; Xia W; Koob MD; Ashe KH
    J Neurosci; 2020 Jan; 40(1):220-236. PubMed ID: 31685653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Caspase-2 cleavage of tau reversibly impairs memory.
    Zhao X; Kotilinek LA; Smith B; Hlynialuk C; Zahs K; Ramsden M; Cleary J; Ashe KH
    Nat Med; 2016 Nov; 22(11):1268-1276. PubMed ID: 27723722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The behavioural phenotype of 14-month-old female TAU58/2 transgenic mice.
    Kreilaus F; Masanetz R; Watt G; Przybyla M; Ittner A; Ittner L; Karl T
    Behav Brain Res; 2021 Jan; 397():112943. PubMed ID: 33017638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
    Sydow A; Mandelkow EM
    Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles.
    Li JG; Chu J; Barrero C; Merali S; Praticò D
    Ann Neurol; 2014 Jun; 75(6):851-63. PubMed ID: 24644038
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.
    Peng Y; Sun J; Hon S; Nylander AN; Xia W; Feng Y; Wang X; Lemere CA
    J Neurosci; 2010 Jun; 30(24):8180-9. PubMed ID: 20554868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.
    Jiang T; Yu JT; Zhu XC; Zhang QQ; Cao L; Wang HF; Tan MS; Gao Q; Qin H; Zhang YD; Tan L
    Neuropharmacology; 2014 Oct; 85():121-30. PubMed ID: 24880087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Formyl Peptide Receptor 2 Deficiency Improves Cognition and Attenuates Tau Hyperphosphorylation and Astrogliosis in a Mouse Model of Alzheimer's Disease.
    Zhang H; Wang D; Gong P; Lin A; Zhang Y; Ye RD; Yu Y
    J Alzheimers Dis; 2019; 67(1):169-179. PubMed ID: 30475772
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits.
    Harris JA; Koyama A; Maeda S; Ho K; Devidze N; Dubal DB; Yu GQ; Masliah E; Mucke L
    PLoS One; 2012; 7(9):e45881. PubMed ID: 23029293
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain.
    Wheeler JM; McMillan P; Strovas TJ; Liachko NF; Amlie-Wolf A; Kow RL; Klein RL; Szot P; Robinson L; Guthrie C; Saxton A; Kanaan NM; Raskind M; Peskind E; Trojanowski JQ; Lee VMY; Wang LS; Keene CD; Bird T; Schellenberg GD; Kraemer B
    Sci Transl Med; 2019 Dec; 11(523):. PubMed ID: 31852801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration.
    Forman MS; Lal D; Zhang B; Dabir DV; Swanson E; Lee VM; Trojanowski JQ
    J Neurosci; 2005 Apr; 25(14):3539-50. PubMed ID: 15814784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.